-
Ardelyx, Inc (ARDX) PT Raised to $7 at Citi, 'Granting of Appeal Unprecedented'
-
Ardelyx, Inc (ARDX) Stock 'Acting Poorly' Despite 50% Up Move - Citi
-
Ardelyx to Participate in Upcoming Investor Conferences
-
Ardelyx, Inc (ARDX) PT Raised to $13 at Citi, Following Clinical Business Update
-
Ardelyx to Participate in Three Upcoming Investor Conferences in September
-
UPDATE: Citi Starts Ardelyx, Inc (ARDX) at Buy; Bullish on Tenapanor
-
Ardelyx (ARDX) Prices 20M Share Upized Offering at $6.25/Sh
-
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
-
Ardelyx (ARDX) Announces Proposed $80M Public Offering of Common Stock
-
Ardelyx Announces Proposed Public Offering of Common Stock
-
Ardelyx, Inc (ARDX) PT Lowered to $11 at Citi
-
Ardelyx (ARDX): PT To $17 After Partnering with KHK in Japan - Citi
-
Ardelyx, Inc (ARDX) PT Lowered to $16 at Citi; 'RDX7675 in Hyperkalemia Discontinued on Safety'
-
Ardelyx, Inc (ARDX) PT Raised to $19 at Citi
-
Pre-Open Movers 10/12: (INFI) (ADRX) (AVXL) Higher; (ACRX) (JILL) (TRVN) Lower (more...)
-
Ardelyx, Inc (ARDX): Selloff Overdone - Citi
-
Citi Highlights Potential Biotech M&A Names Following Relypsa Deal (ADRX) (OPHT) (PBYI) (PTLA) (RARE) (VSAR)
-
Notable Analyst Rating Changes 3/9: (FEYE) (CBS) (RBS) Upgraded; (GRPN) (DSX) (FTR) Downgraded
-
Citi Starts Ardelyx, Inc (ARDX) at Buy
-
Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
-
Ardelyx (ARDX) Prices 7.5M Common Stock Offering at $10/Share
-
Ardelyx Announces Pricing of Public Offering of Common Stock
-
Ardelyx (ARDX) to Offer $75M in Common Stock
-
Ardelyx Announces Proposed Public Offering of Common Stock
-
Citi Starts Ardelyx, Inc (ARDX) at Buy
-
Ardelyx (ARDX) IPO Opens Modestly Higher
-
Ardelyx (ARDX) IPO Prices Upsized IPO at $14

